Shattuck Labs provides pipeline and financial update

Shattuck Labs announced a strategic pipeline prioritization to include the discontinuation of its clinical program, SL-172154. The company will turn its focus to SL-325, its DR3 antagonist antibody, and plans initial clinical development in patients with IBD, where TL1A/DR3 blocking antibodies have demonstrated compelling monotherapy efficacy. Shattuck to discontinue SL-172154 program and pivot to pipeline compound: approval of SL-172154 in TP53m AML and HR-MDS would require meaningful improvement in OS in large-scale, randomized studies. The company saw only modest improvements in OS in its Phase 1 trial and historically some erosion in efficacy would be expected in larger, randomized trials. Given Shattuck’s current resources, the lack of a definitive OS benefit to date, and that no CD47 inhibitor has shown a significant efficacy signal in any indication to date, the company has chosen to reallocate its resources to drive SL-325 through Phase 1 clinical development. Shattuck and Ono Pharmaceutical mutually agreed to terminate their license agreement collaborating on preclinical development of certain compounds. Shattuck’s lead candidate, SL-325, is a potentially first-in-class DR3 antagonist antibody for the treatment of IBD and other inflammatory autoimmune diseases. Shattuck expects to file an IND for SL-325 in 3Q25. As of June 30, cash and cash equivalents and investments were $105.3M. Shattuck has implemented a restructuring plan to prioritize the development of the company’s DR3 program following the discontinuation of SL-172154. Approximately 40% of Shattuck’s workforce will be impacted by the changes. The company expects to complete the reduction in force in Q4. The company believes its cash and cash equivalents and investments will be sufficient to fund its planned operations into 2027, beyond results from its planned Phase 1 clinical trial of SL-325.